Jiangsu Hengrui Medicine Company Ltd. is a pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui was established in 1970 and listed in Shanghai Stock Exchange in 2000. The company ranks top 30 worldwide by market capitalization of about 50 billion USD and is home to more than 24,700 employees worldwide.
Hengrui produces medicines for cancer drugs, contrast agents, and surgical medicines, as well as being a lead member of the National Anti-Tumor Medicine Technology Innovation Industry-Education-Research Alliance. Hengrui owns a National Targeted Drug Engineering Technology Research Center, and a post-doctoral research station. Hengrui owns 10 R&D centers globally, where over 3,000 research staffs work on hundreds of therapeutic candidates. Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices.
Since the outbreak of Covid-19 people have become reliant on existing drugs to treat symptoms of the coronavirus. Many of China's pharma companies have been integral to aiding this current crisis through both drug research and provisions. This includes Hengrui who sent $400,000 worth of its pegfilgrastim drug, which targets regrowth of white blood cells, direct to Wuhan in its first round of donations.
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.